AHP/INTERNEURON REDUX PATIENT PACKAGE INSERT TO BE DEVELOPED; ANTI-OBESITY AGENT WILL COST $2.40/DAY AT JUNE LAUNCH; DEXFENFLURAMINE IS DEA SCHEDULE IV
Executive Summary
A patient package insert for Interneuron/Wyeth-Ayerst's anti-obesity drug Redux will be submitted to FDA as an NDA supplement, according to the agency's April 29 approval letter for the anti-obesity agent dexfenfluramine.